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In the past, most patients with sickle cell disease (SCD)
were not placed on regular transfusion regimens. How-
ever, several recent reports have recommended transfusion
therapy for this patient population to prevent primary or
recurrent neurovascular complications (1). Although
transfusions may help to minimize disease-speciﬁc morbid-
ity and mortality in this condition, they are not without
their own side effects. In b-thalassemia major patients,
chronic transfusion therapy often results in massive iron
overload in the liver, heart, and endocrine glands, leading
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14.1 ± 13.2 Units ⁄ yr, and the mean hemoglobin level was 9.0 g ⁄dL. PHT was detected in 6 (27.3%)
patients, but none had evidence of heart failure. The mean serum ferritin, LIC, and NTBI levels were
997.7 ng ⁄mL, 4.6 mg Fe ⁄g dw, and 1.1 ± 2.2, respectively. TR was a much better predictor of iron burden
(LIC, ferritin, NTBI) than TLT. In fact, TR less than 10 Units ⁄ yr did not produce significant iron overload
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strates that TR is a stronger predictor of iron overload than TLT. It also confirms cardiac sparing in patients
with SCD, even in subjects with significant transfusion burden, systemic and hepatic iron overload.
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to signiﬁcant organ dysfunction (2). In fact, accumulation
of cardiac iron is the leading cause of death in transfused
patients with b-thalassemia major (TM) (3). In contrast to
thalassemia, anecdotal reports suggest that patients with
SCD may be protected from iron-related cardiac damage
(4). We herein evaluate the status of cardiac iron loading
using magnetic resonance imaging (MRI) T2* in a cohort
of Lebanese patients with SCD.
Patients and methods
This was a cross-sectional study of randomly selected
patients with SCD treated at two comprehensive Leba-
nese SCD centers: Raﬁk Hariri University Hospital
(RHUH) and Nini hospital. The sampling frame con-
sisted of 200 non-chelated SCD patients >2 yr of age,
and a simple random sample of 23 patients was
obtained, in accordance with the availability of fund-
ing. Patient charts were reviewed for demographics
(age and gender), status of the spleen, comorbid
illnesses or infections, and total lifetime transfusions
(TLT). Transfusion rate (TR) was calculated according
to the following formula: [TLT (Units) ⁄ years receiving
transfusion]. All transfusions were non-exchange with
an approximate volume of 300 ml ⁄Unit. Written
informed consent was provided by all patients, and
approval was obtained from ethical committees of both
institutions.
Laboratory tests
Blood samples were obtained for assessment of hemoglo-
bin (Hb), steady-state serum ferritin (SF), and liver
enzyme levels. Serum non-transferrin-bound iron (NTBI)
(stored at )20C) content was assayed by high perfor-
mance liquid chromatography (HPLC) according to the
methods of Porter et al. (5).
Echocardiography
Doppler echocardiography was performed to detect pul-
monary hypertension (PHT) and assess left ventricular
ejection fraction (LVEF). PHT was deﬁned as a systolic
pulmonary artery pressure greater than 40 mmHg, which
corresponds to a tricuspid regurgitant velocity of
3–3.5 m ⁄ s.
Magnetic resonance imaging
Direct determination of liver iron concentration (LIC)
was performed using R2 magnetic resonance imaging
(MRI) using established methodology (6). Cardiac iron
levels were measured by MRI T2*. Patients were scanned
with MRI 1.5 T Magnetom Avanto Siemens using
a multiecho breath-hold sequence [echo times (TE)
5Æ6–17Æ6 ms] as described by Wood JC (7). In this study,
cardiac T2* >20 ms was considered normal.
Statistical analysis
Data are expressed as means ± standard deviation (SD)
or percentages where appropriate. All univariate compar-
isons among continuous variables (LIC, T2*, ferritin,
NTBI, TR, TLT) were evaluated with Pearson’s (r) and
Spearman’s (rs) correlation coefﬁcients. Comparisons of
continuous and categorical variables (gender, splenec-
tomy, PHT) were evaluated using the independent t-test.
All p-values are two sided with the level of signiﬁcance
set at <0.05.
Results
Data from 23 patients (17 SS; 6 S ⁄b-Thal) were included
in the analysis (Table 1). The mean age was 24.4 ± 9.7 yr,
with a male to female ratio of 15:8. A total of 9 (49.9%)
patients were splenectomized. TLT was 73.8 ± 80.6 Units
with a TR of 14.1 ± 13.2 Units ⁄ yr and a mean Hb level
of 9.0 ± 1.4 g ⁄dL. Neither hepatitis C or B infection, nor
elevation in liver enzymes was documented in any of the
patients. PHT was detected in 6 (27.3%) patients, but none
had evidence of heart failure by modiﬁed Framingham
criteria (8) (mean LVEF was 64.6 ± 5.3%).
Iron overload parameters
The mean ± SD values of SF, LIC, and NTBI levels
were 997.7 ± 1110.9 ng ⁄mL, 4.6 ± 7.0 mg Fe ⁄ g dry
weight (dw), and 1.1 ± 2.2 lmol ⁄L, respectively. Iron
burden was independent of gender and spleen status. SF
was correlated with LIC (rs = 0.585; P = 0.003). TLT
was a fair predictor of iron for both LIC (Fig. 1A) and
serum ferritin (Fig. 1B). Of note, ﬁve patients who had
received more than 100 Units [approximate to 24 g of
iron, (9)] had LIC’s less than 5 mg Fe ⁄ g dw and SF val-
ues under 900 ng ⁄mL. In contrast, TR was a much
stronger predictor of LIC (rs = 0.782; P < 0.001,
Fig. 2A) and SF (rs = 0.633; P = 0.001, Fig. 2B). No
patient with a TR less than 10 Units ⁄ yr had a LIC
greater than 2.5 mg Fe ⁄ g dw, indicating that iron from
infrequent transfusions did not appear to accumulate
over time. Once this threshold was exceeded, LIC rose
linearly with TR. NTBI also rises proportionally to TR
(Fig. 3). The four highest NTBI levels (>3.1 lmol ⁄L)
occur in patients with TR >10 Units ⁄ yr, although
several patients with increased TR exhibit normal NTBI
levels.
None of the patients had evidence of cardiac iron
overload (mean cardiac T2* = 37.3 ± 6.2 ms; range:
Cardiac iron in sickle cell disease Inati et al.
566 ª 2009 John Wiley & Sons A/S
21.9–46.8 ms; Fig. 4). So, there was no statistically signif-
icant difference between mean cardiac T2* values in
males and females (36.6 vs. 38.5 ms; P = 0.510), SS and
S ⁄b-Thal (36.9 vs. 38.1 ms; P = 0.923), splenectomized
and non-splenectomized patients (35.4 vs. 37.9 ms;
P = 0.789), or between patients with and without PHT
(38.1 vs. 36.4 ms; P = 0.171). There was also no signiﬁ-
cant correlation between 1 ⁄T2* values and any of SF
(rs = 0.130; P = 0.553), LIC (rs = )0.092; P = 0.685),
NTBI (rs = )0.191; P = 0.382), age (rs = )0.336;
P = 0.117), Hb level (rs = 0.135; P = 0.548), TR
(rs = )0.073; P = 0.742), or LVEF (rs = 0.232;
P = 0.312).
Discussion
The use of MRI to detect cardiac and hepatic iron over-
load is becoming increasingly common because of its
non-invasive and highly reproducible nature and pro-
vides new insights into the dynamics of iron overload
(10). None of our patients exhibited detectable cardiac
iron overload, in agreement to all previous MRI studies
in SCD patients (11–15). More importantly, our data
demonstrate that intermittent transfusions (<10 Units ⁄
yr) do not produce signiﬁcant somatic iron overload in
SCD patients, suggesting that spontaneous iron losses
may be higher than previously recognized. For reference,
ten 300-ml transfusions can be balanced by a net excre-
tion of 6.6 mg iron per day, or roughly 0.11 mg ⁄kg ⁄d
for a 60-kg patient. Iron excretion rates of no more than
2 mg ⁄d are typically quoted for normal subjects (16).
SCD patients have greater intravascular hemolysis, heme
scavenging, heme ﬁltration, and renal tubular absorption,
which could potentially increase renal and fecal iron
losses relative to non-hemolytic anemias (17, 18). In fact,
iron elimination rates as high as 10.8 mg ⁄kg ⁄d have been
described in patients with mechanical hemolysis (17, 18).
Regardless of the iron loss mechanism, iron elimina-
tion rates of 0.11 mg ⁄kg ⁄d cannot be ignored when con-
sidering iron overload risk. Table 2 lists the average
transfusion rates from the Novartis-sponsored 108 and
109 trials for ﬁve different anemias and a hypothetical
‘net’ accumulation rate if all subgroups are assumed to
eliminate iron at that rate (19, 20). Based on these data,
one would expect TM patients to accumulate iron 2.2-
fold faster than patients with SCD. If spontaneous iron
losses were 2 mg ⁄d (0.03 mg ⁄kg ⁄d) in the TM patients,
this disparity would be nearly 3-fold.
These data offer another mechanism to explain why
SCD patients may be protected from cardiac siderosis.
Table 1 Patients’ characteristics
Patient
Age
(years) Sex
Hb
electrophoresis Splenectomy
TLT
(Units)
TR
(Units ⁄ year)
LVEF
(%) PHT
Hb
(g ⁄ dL)
SF
(ng ⁄ mL)
LIC
(Fe ⁄ g dw)
NTBI
(lmol ⁄ L)
Cardiac
T2* (ms)
1 27 M SS Y 166 20.8 67 N 9.2 1300 6.9 6.14 30.4
2 24 M SS N 8 8.0 58 Y 10.6 188 0.9 )0.01 43.7
3 16 M SS N 18 6.0 73 Y 10.3 989 1.1 0.92 35.5
4 14 M SS N 8 8.0 67 N 8.2 253 0.3 )0.27 42.4
5 21 M ST N 3 3.0 65 N 7.8 496 0.7 1.54 31.4
6 11 M ST Y 20 10.0 61 Y 9.4 486 1.2 0.30 32.9
7 17 F SS N 25 12.5 64 N 8.7 527 1.2 )0.89 29.7
8 36 M SS N 1 1.0 60 N 6.1 41 1.5 )1.43 38.8
9 24 F ST Y 6 6.0 75 N 9.6 76 2.2 )1.52 38.8
10 49 M SS N 8 8.0 65 N 9.0 323 1.3 0.20 38.6
11 21 M SS N 120 15.0 65 Y 10.0 391 4.6 1.12 36.3
12 28 F SS N 50 6.3 63 N 11.6 719 1.2 1.40 33.5
13 30 M SS N 120 12.0 64 N 7.1 842 3.2 0.26 39.1
14 24 F SS Y 32 5.3 60 N 10.9 335 1.0 -0.26 32.6
15 38 M SS N 8 8.0 58 Y 8.1 154 0.3 0.43 39.6
16 36 F ST N 10 10.0 67 N 7.3 161 1.3 0.13 35.4
17 28 F SS N 300 50.0 69 N 7.4 2670 21.0 6.37 46.8
18 26 F ST Y 52 8.7 63 N 9.0 679 1.8 2.33 45.3
19 27 F SS N 139 34.8 62 N 9.2 3430 21.5 3.12 45.7
20 24 M SS N 133 13.3 58 Y 7.6 2550 3.3 4.90 40.8
21 18 M SS Y 145 14.5 76 N 10.0 3090 5.1 1.07 32.6
22 19 M ST N 125 12.5 61 N 10.1 177 2.4 -0.51 45.0
23 4 M SS N 200 50.0 65 N 8.9 3070 21.7 -0.97 21.9
M, male; F, female; Y, yes; N, no; SS, homozygous sickle cell; ST, sickle b-thalassemia; TLT, total lifetime transfusions; TR, transfusion rate,
LVEF, left ventricular ejection fraction; PHT, pulmonary hypertension; Hb, hemoglobin; SF, serum ferritin; LIC, liver iron concentration; dw, dry
weight; and NTBI, non-transferrin-bound iron.
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Transfusion therapy is often sporadic and may not reach
the threshold for signiﬁcant cumulative buildup. Even
when aggressive chronic transfusion therapy is used, it is
often started later in life of SCD patients and at a lower
intensity, lowering the total transfusional exposures for
any given patient age when compared to thalassemia
major patients. Vichinsky et al. (21) attributed the
absence of organ-speciﬁc iron overload to shorter and
less intense transfusional exposure to SCD when com-
pared to TM patients. Our ﬁndings echo previous reports
in which the speciﬁc biology of hemoglobinopathy and
related transfusional history play a major role in the rate
and distribution of iron overload (22–26).
However, not all of the disparity can be explained by
disparities in transfusion practices or spontaneous losses.
Wood et al. (11) showed that heavily iron-loaded SCD
patients (mean LIC 19.3 mg Fe ⁄ g dw) had normal car-
diac T2* despite receiving monthly transfusions for an
average of 9.3 yr (range 4–24 yr) (11, 27). Under condi-
tions of iron homeostasis, cardiac iron needs are supplied
via highly regulated transferrin-mediated uptake mecha-
nisms. During iron overloading, transferrin becomes sat-
urated and toxic NTBI begins to appear in the
circulation. NTBI readily enters cardiomyocytes, pre-
dominantly as ferrous iron via L-type Ca2+ (voltage-
dependent) channels, raising the levels of labile cardiac
iron (28). The mean NTBI level in this cohort is rela-
tively lower than that reported in TM patients conﬁrm-
ing observations of previous reports (29). In the study by
Walter et al. (29), SCD patients had 2-fold lower NTBI
levels than TM patients (1.9 vs. 4.0 lmol ⁄L) despite
higher LIC (15.0 vs. 9.2 mg Fe ⁄ g dw). Several theories
have been postulated to explain this difference. Increased
cytokines (such as IL-10) may explain the lower NTBI
levels in SCD when compared with TM patients (30). It
has also been suggested that the NTBI of SCD patients
may be taken up by the reticuloendothelial system, spar-
ing the parenchymal tissues of injury (31). Inﬂammation
in general may be further contributing to the lower
NTBI levels observed in SCD, further protecting against
tissue injury by removing a source of circulating labile
iron (29). This may partly explain why transfused
patients with SCD have a conspicuous absence of target
organ iron-overload.
The relationship between cardiac T2* values and iron
balance is quite complicated because the mechanisms
Figure 1 Correlation between (A) liver iron
concentration (LIC) and total lifetime trans-
fusions and (B) serum ferritin and total lifetime
transfusions.
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and kinetics of cardiac iron uptake and clearance differ
from the liver (10, 15). Cardiac T2* does not correlate
with SF concentration and LIC in cross-sectional analy-
sis, while longitudinal studies continue to imply a causal
relationship (10–15). Wood and Noetzli (10, 11) demon-
strated a signiﬁcant latency to T2* changes, relative to
liver accumulation, suggesting a long delay between poor
Figure 2 Correlation between (A) liver iron
concentration (LIC) and transfusion rate and
(B) serum ferritin and transfusion rate.
Figure 3 Correlation between transfusion rate and non-transferrin-
bound iron (NTBI); patient 23 (hollow diamond) was excluded from
correlation.
Figure 4 Cardiac T2* MRI showing heavy iron loading in the liver
(dark tissue) yet heart sparing; patient 19.
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iron control and detectable cardiac iron deposition.
Other MRI work suggests that a ‘critical’ liver saturation
is necessary to achieve positive cardiac iron balance (27).
This may explain the absence of cardiac iron overload
even in patients who had SF >2500 ng ⁄mL or LIC
>15 mg Fe ⁄ g dw, both of which are associated with
higher incidence of cardiac decompensation (32). Our
present work also reinforces the critical importance of
transfusion rate in determining iron burden and iron risk
(33). However, careful longitudinal studies of cardiac
and liver iron will be necessary to resolve these interde-
pendencies.
Despite the aforementioned evidence on cardiac spar-
ing in SCD, some reports have shown that accumulation
of toxic iron species within myocytes is not necessary to
induce cardiac dysfunction, and only initial exposure to
NTBI maybe enough to cause damage to cardiac tissue.
The latter entails that even without evidence of cardiac
siderosis, SCD patients may still be at risk of iron-related
organ dysfunction secondary to hepatic iron overload
with subsequent release of toxic species, and thus high-
lighting the need for effective iron-chelation therapy in
this patient population (34–36).
In conclusion, current radiological evidence supports
cardiac sparing in iron-overloaded patients with SCD.
However, our study included a small number of patients
and larger prospective studies taking into consideration.
TR, TLT, serial SF, NTBI, and LIC measurements and
longer term follow-up are necessary to conﬁrm and
better understand this phenomenon. Moreover, several
factors that may affect iron burden and organ toxicity
should also be addressed including ineffective erythro-
poiesis, hemochromatosis genes, the role of hepcidin,
gastrointestinal iron metabolism, and urinary iron loss.
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